SGYP lead drug is "plecanatide" for IBS and it works with less side effects then Linzess
the drug has done great through all the clinical trials. expect great things. also worth mentioning IRWD who owns only 40% of Linzess is worth 1.5bb. which would make SGYP worth over 3bb due to the fact they own 100% of Plecanatide. SGYP does have another drug which is a synthetic form for the treatment of IBD called SP-333 which is in its first clinical trial. I"M HERE FOR PLECANTIDE THAT TREATS IBS. SP-333 IS A BONUS.... THAT THE BOTTOM LINE.... LONG AND STRONG. SEE YOU AT 25 BY YEAR END.